United Kingdom: Healthcare

An investigation is underway after multiple sclerosis patients in the UK reported adverse effects following a switch from the originator medicine Tysabri to its biosimilar Tyruko. Despite regulatory approval confirming no clinically meaningful differences between the two natalizumab-based treatments, subtle variations in manufacturing processes, formulation buffers, and molecular characteristics may explain why some patients have experienced worsening symptoms or side effects.

Investigations into NHS paediatric audiology services have revealed systemic failures affecting hundreds of children, including delayed assessments and missed hearing loss diagnoses that may have impacted speech, language and educational development. Families affected by these failures in care may have legal options to pursue compensation where delays caused avoidable harm and lost opportunities for early intervention. Understanding the scope of these failures and the potential consequences for children's d

The European Patent Convention allows medical use claims for substances and compositions, but not devices. Recent case law has shifted the approach to determining what qualifies as a "substance or composition," moving away from mode-of-action analysis toward examining the claimed material itself. This evolution raises critical questions about claim drafting and the scope of patent protection for medical technologies.

The Amos Report examines whether this latest inquiry into UK maternity care will finally drive meaningful improvement or simply repeat lessons already identified by previous investigations. With decades of warnings about avoidable harm, persistent inequalities, and failures to learn from past mistakes, the report raises critical questions about systemic accountability and the effectiveness of reform efforts. Will this become another report that gathers dust, or a genuine catalyst for safer, more equitable m

May 2026 saw continued momentum across the European Union and United Kingdom toward modernizing and streamlining the regulatory landscape for digital health, with a particular focus on accommodating AI-enabled technologies while reducing unnecessary complexity.

The UK and US FemTech markets have nearly tripled in size over five years, with revenues projected to reach $3.8 billion and $32.3 billion respectively by 2030.

The MHRA’s proposed rare disease therapies regulatory framework (“the Proposed Framework”) represents an ambitious attempt to redesign medicines regulation around the realities of rare disease development.

The MHRA has launched a consultation on proposed updates to the definition of gene therapy medicinal products (“GTMPs”) under the UK Human Medicines Regulations 2012 (“HMRs”).

Personal injury claims increasingly involve significant mental health consequences, from anxiety and PTSD to depression and emotional distress. Understanding the complex relationship between physical trauma and psychological harm is essential for victims seeking proper support and compensation, particularly when psychiatric injuries occur alongside or independently of physical injuries.